223557-20-8

Basic information

• Product Name: 1-Bromo-4-(propane-1-sulfonyl)benzene
• Synonyms: 1-Bromo-4-(propane-1-sulfonyl)benzene;1-BroMo-4-(propylsulfonyl)benzene
• CAS NO: 223557-20-8
• Molecular Formula: C₉H₁₁BrO₂S
• Molecular Weight: 263.15144
• Mol File: 223557-20-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Bromo-4-(propane-1-sulfonyl)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Bromo-4-(propane-1-sulfonyl)benzene(223557-20-8)
• EPA Substance Registry System: 1-Bromo-4-(propane-1-sulfonyl)benzene(223557-20-8)

Safety Data

• Hazardous Substances Data: 223557-20-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry:
1-Bromo-4-(propane-1-sulfonyl)benzene is utilized as a reagent in various synthetic reactions within the field of organic chemistry. Its reactivity is leveraged in palladium-catalyzed cross-coupling reactions and nucleophilic aromatic substitution reactions, which are fundamental processes in the synthesis of complex organic molecules.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 1-Bromo-4-(propane-1-sulfonyl)benzene serves as a key intermediate in the synthesis of various pharmaceuticals. Its unique functional groups facilitate the creation of new drug candidates with potential therapeutic applications.
Used in Agrochemical Production:
Similarly, in agrochemicals, 1-Bromo-4-(propane-1-sulfonyl)benzene is employed in the synthesis of compounds that have applications in agriculture, such as pesticides and herbicides, contributing to the development of more effective and targeted products for crop protection.
Used as a Building Block in Organic Compounds Production:
1-Bromo-4-(propane-1-sulfonyl)benzene is recognized as a versatile building block for the preparation of other functionalized benzene derivatives. Its role as an intermediate is crucial in the production of a wide range of organic compounds, highlighting its importance in the broader scope of chemical manufacturing and research.

Upstream product

• 106-94-5 propyl bromide 
• 106-53-6 para-bromobenzenethiol 
• 5467-74-3 4-Bromophenylboronic acid 
• 76542-19-3 4-bromophenyl(1-propyl)sulfane 

Downstream Products

• 876617-07-1 4,4,5,5-tetramethyl-2-[4-(propane-1-sulfonyl)phenyl][1,3,2]dioxaborolane 
• 1286238-52-5 3-amino-N-phenyl-6-(4-(propylsulfonyl)phenyl)pyrazine-2-carboxamide 
• 223555-38-2 (4-tributylstannylphenyl)propylsulfone 

Relevant articles and documents

Palladium-Catalyzed Synthesis of (Hetero)Aryl Alkyl Sulfones from (Hetero)Aryl Boronic Acids, Unactivated Alkyl Halides, and Potassium Metabisulfite

A palladium-catalyzed one-step synthesis of (hetero)aryl alkyl sulfones from (hetero)arylboronic acids, potassium metabisulfite, and unactivated or activated alkylhalides is described. This transformation is of broad scope, occurs under mild conditions, and employs readily available reactants. A stoichiometric experiment has led to the isolation of a catalytically active dimeric palladium sulfinate complex, which was characterized by X-ray diffraction analysis.

Identification of biaryl sulfone derivatives as antagonists of the histamine H3 receptor: Discovery of (R)-1-(2-(4′-(3- methoxypropylsulfonyl)biphenyl-4-yl)ethyl)-2-methylpyrrolidine (APD916)

The design of a new clinical candidate histamine-H3 receptor antagonist for the potential treatment of excessive daytime sleepiness (EDS) is described. Phenethyl-R-2-methylpyrrolidine containing biphenylsulfonamide compounds were modified by re

OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and using such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. Formula I (I) or a pharmaceutically acceptable salt thereof, wherein: m is independenlly at each occurrence 1, 2, or 3, Z independently represents carbon (substituted with hydrogen or the optional substituents indicated herein) or nitrogen, provided that when Z is nitrogen then R6 is not attached to Z; R1 and R2 are independently -(C1-C7) alkyl(optionally substituted with one to three halogens), or R1 and R2 and the nitrogen to which they are attached form an azetidinyl ring, a pyrrolidinyl ring, or a piperidinyl ring, wherein further the azetidinyl, pyrrolidinyl, or piperidinyl ring so formed may be optionally substituted one to three times with R5; R6 is independently at each occurrence -H, -halogen, or -CH3.